Lannett Advances Its Insulin Glargine Biosimilar
IND Submission With FDA Announced For Proposed Lantus Rival Developed With HEC
As Lannett announced the submission of an IND with the FDA for the proposed insulin glargine biosimilar rival to Lantus that it is developing with HEC, the company set out key development and commercialization milestones for the product in 2022, 2023 and 2024.
